OCS Oculis Holding AG
53
$12.10
$0.0301
(0.25%)
| Watchers | 53 |
| 52-Wk Low | $9.05 |
| 52-Wk High | $14.50 |
| Market Cap | $442.36M |
| Volume | 18,043.00 |
| 52-Wk High | $14.50 |
| 52-Wk Low | $9.05 |
Oculis to Participate at Upcoming April Investor ConferencesGlobe Newswire • about 1 month ago
ZUG, Switzerland and BOSTON, April 04, 2024 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS) ( Oculis ), a global biopharmaceutical company purposefully driven to save sight and improve eye...
Share to Feed
Oculis Holding AG (NASDAQ:OCS Free Report) Stock analysts at Leerink Partnrs issued their Q1 2024 earnings estimates for shares of Oculis in a research report issued to clients and...
Oculis Holding AG (NASDAQ:OCS Free Report) Equities research analysts at Leerink Partnrs issued their Q1 2024 earnings per share estimates for shares of Oculis in a research note...
Shares of Oculis Holding AG (NASDAQ:OCS Get Free Report) have received an average rating of Buy from the nine research firms that are currently covering the stock, Marketbeat...
A successful year including NASDAQ listing and positive results from two Phase 3 programs in OCS-01: Phase 3 Stage 1 DIAMOND trial for Diabetic Macular Edema (DME), and Phase 3 OPTIMIZE-1 trial for...
Oculis Holding AG (NASDAQ:OCS Get Free Report) has been assigned a consensus recommendation of Buy from the nine brokerages that are covering the company, Marketbeat Ratings...
Completed enrollment in Phase 2b RELIEF trial of Licaminlimab (OCS-02), anti-TNF (tumor necrosis factor) alpha eye drops in Dry Eye Disease (DED); topline results expected in Q2 2024Second Phase 3...
Wolverine Asset Management LLC acquired a new stake in Oculis Holding AG (NASDAQ:OCS Free Report) during the third quarter, according to its most recent disclosure with the Securities and...
ZUG, Switzerland and BOSTON, Jan. 29, 2024 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS) ( Oculis ), a global biopharmaceutical company purposefully driven to save sight and improve eye care...
Shares of Oculis Holding AG (NASDAQ:OCS Get Free Report) have been given a consensus recommendation of Buy by the nine ratings firms that are covering the stock, MarketBeat...